Barinthus Biotherapeutics (ADR) (BRNS)
Develops immune-tolerance therapies for celiac disease while seeking partners for legacy viral-vector programs.
Something off on this page? Send us feedback.
Develops VTP-1000, an antigen-specific immune-tolerance program for celiac disease. Formerly Vaccitech, it is a small, U.S.-centered clinical-stage company seeking partners for its viral-vector portfolio.
Originated as a Jenner Institute, University of Oxford spinout and became Barinthus after operating as Vaccitech. The business is a clinical-stage immunotherapy company centered on antigen-specific immune tolerance, with VTP-1000 its directly prioritized program for celiac disease.
Future operations are focused in Germantown, Maryland after a restructuring and planned U.K.-site closure. The company seeks partners to advance VTP-300 for chronic hepatitis B and other legacy viral-vector assets rather than funding them as its direct priority.
A proposed combination with Clywedog Therapeutics remained pending in the latest company update; the reported future name and ticker were conditional on closing. Direct development therefore depends on VTP-1000 clinical progress, while the legacy portfolio depends on partner-led advancement.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $59.3M · Total debt $10.3M · Total assets $81.9M · Shareholders' equity $57.1M
- Revenue
- $0
- Operating income
- −$11.0M
- Net income
- −$10.6M
No dividends on record.
| Insiders2 holders · as of Feb 11, 2025 | 9.85% | 4.03M ADS | |
| Strategic holders1 holder · as of Apr 13, 2026 | 6.69% | 2.73M ADS | |
| Otherremainder | 83.46% | 34.09M ADS |
40.85M ADS as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Frank W. CawoodInsider | 8.29% | 3.38M | 13Gfiled Feb 11, 2025 ↗ |
International Generosity Foundation TrustStrategic | 6.69% | 2.73M | 13Dfiled Apr 13, 2026 ↗ |
Geoffrey LynnInsiderofficer: Chief Scientific Officer | 1.57% | 640,639 ordinary | Form 4filed Dec 31, 2024 ↗ |
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Takeda (ADR)
Celiac therapies targeting gluten-driven intestinal injury
- Teva (ADR)
Phase 2a anti-IL-15 therapy for celiac disease
- Sanofi (ADR)
Phase 2a/b OX40L blockade for non-responsive celiac disease
- GSK (ADR)
Phase 3 functional-cure regimen for chronic hepatitis B
- VirBio
Partner-dependent chronic-HBV functional-cure combination program
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Barinthus Biotherapeutics (ADR) | $0.7270 | −6.18% | $30.4M | — | — | — | — |
| Takeda (ADR) | $18.59 | +0.81% | $58.65B | 51.2 | 56.8 | 2.0 | +5.8% |
| Teva (ADR) | $37.45 | −0.05% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Sanofi (ADR) | $44.54 | +0.17% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| GSK (ADR) | $50.57 | +0.29% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| VirBio | $11.58 | +0.74% | $1.94B | — | — | 6.4 | +19,582.5% |
| Median | 56.9 | 13.3 | 2.2 | +5.8% |